Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) Equity Average: 2010-2024

Historic Equity Average for China Pharma Holdings (CPHI) over the last 15 years, with Dec 2024 value amounting to $7.6 million.

  • China Pharma Holdings' Equity Average rose 6.02% to $7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.4 million, marking a year-over-year increase of 6.02%. This contributed to the annual value of $7.6 million for FY2024, which is 29.44% up from last year.
  • As of FY2024, China Pharma Holdings' Equity Average stood at $7.6 million, which was up 29.44% from $5.9 million recorded in FY2023.
  • Over the past 5 years, China Pharma Holdings' Equity Average peaked at $8.6 million during FY2020, and registered a low of $5.2 million during FY2022.
  • For the 3-year period, China Pharma Holdings' Equity Average averaged around $6.2 million, with its median value being $5.9 million (2023).
  • Per our database at Business Quant, China Pharma Holdings' Equity Average tumbled by 56.28% in 2020 and then climbed by 29.44% in 2024.
  • Over the past 5 years, China Pharma Holdings' Equity Average (Yearly) stood at $8.6 million in 2020, then declined by 18.67% to $7.0 million in 2021, then fell by 26.49% to $5.2 million in 2022, then rose by 13.94% to $5.9 million in 2023, then climbed by 29.44% to $7.6 million in 2024.